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EffectsofSmokingStatuson Long-TermMortality,
MorbiditysndNeedforAdditionalCoronsry
InterventionsAfterSuccessfulPercutaneous
CoronaryRevascularization
K.N. Garratt, D.E. Grill, A. Lerman, V. Mathew, D.R. Holmes. Jr.
Mayo Clinic, Roohestei MN, USA
The aim of this study waeto examine the effect of smoking status on outcome
after percutaneous mronary revascularization (PCR). All patients after suc-
cessful PCR were followed over 16 yeacs (mean 4.5 + 3.7 yeare). Patienta
were divided into 4 groups: nonsmokers (1,n = 2009), former smokers (11,n
= 2259), quitting smokers immediately after PCR (Ill, n = 435) and persisting
smokers (IV, n = 734). At baseline, smokers (Ill and IV) were younger than
I and U,had shorter duration of angina and fewer comorbid conditions, but
had more prior myocardial infarction. Smokers had less extensive coronary
artery disease and prior coronary bypass surgety (CABG) and higher rates
of complete revascularization.
After adjustment for baseline characteristics, smokers had greater risk of
death (RR = 1.20 and RR = 1.74, p < 0.001) and Q-wave infarction (RR=
1.44 and RR= 2.06, p = 0.11), but leas of PCR (RR = 0.80 and RR= 0.87,
p < 0.001) and CABG (RR = 0.71 and RR = 0.68, p = 0.002) relative to
non-smokers. By 7 years, patients who continued to smoke after PCR had
greater risk of death than those who quit immediately (RR= 1.48, p = 0.04).
Conckrsion: Accounting for their favorable clinical and angiographic pro-
file, smokers are at greater risk of death or Q-wave infarction after successful
PCR. Smokers have fawer revascularfzation procedures during follow-up.
This study demonstrates that quilting smoking after PCR reduces risk of
death by 33%.
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1718-41 LessOnsfromthewestofS~otlandCoronsfY
PreventionStudy(WOSCOPS):Whoshouldba
trested
J. Shepherd for the WOSCOPS Publications Committee. University
Depatiment of Pathological Biochemistry Glasgow Royal Infirmary
Glasgow G4 OSI$ USA
WOSCOPS recently defined the benefits of pravastatin therapy in the pre-
vention of coronary heart disease (CHD) events in middle-aged hyperc-
holeaterolemic men without prior myocardial infarction. Individuals at highest
riak exhibited the greateat accumulation of events and gained most from
treatment.
The significant univariate predictors of outcome were smoking habit, di-
abetes mellitus, history of hypertension, nitrate consumption, minor ECG
abnormality, angina peotoris, family history of CHD, widowhood, educational
achievement and employment status. Continuous variables of predictive eig-
nifioenoa were age, height, blood presaure, VLDL cholesterol, HDL choles-
terol, log Triglyceride] and total cholesterol/HDL cholesterol ratio.
The above elementa were used to calculate individual risk scores and
thereby to determine the probability of a major coronary event during the
five year follow-up period of the study. On the strangth of this we concluded
that targeted screening is most cost effective in identifying at-risk patients.
Compared with the untargeted approach, the former would identify, in the
top quartile of the WOSCOPS risk distribution, 45Y0of the prima~ endpoints
and 64% of the CHD deaths. These results reinforce the merits of the new
joint European and NCEP guidelines for the preventive management of
CHD.
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El7185 Lipoprotein(a),Lipids,AspirinandRiskofMyocardialInfarctioninthePhysicians’HealthStudy
A.A. Arfyo, P.M. Ridker, M.J. Stampfer, C~H.Hennekens. Brfgframand
Women’s Hb.spital,Harvar’dMedioal.School, Boston, MA, USA
Previously reported data from the Physicians’ Health Study (PHS) indicate no
aaaooiation between lipoprotein(a) (Lp[a]) and subsequent risk of myooardial
infarction (Ml) among a large cohort of middle-aged men followed for an
average of 60.2 months. In a follow-up analysis of 296 confirmed cases of Ml
and 296 controls, we evaluated for evidence of association between Lp(a)
and cardiovascular risk among those with and without hypetlipidemia and
among those randomized to aspirin and placebo.
Among those with total cholesterol (Tc) > = 200 mg/dL, the age-and
smoking-adjusted relative risks (RRs) of first Ml associated with Lp(a) level
above the 25th, 50fh, 75th, 90th, and 95th percentile of the control distribution
were 0.9, 1.1, 1.8, 1.7, 1.0; (all p-values nonsignificant, p-trend =0.5). Among
those with total cholesterol <200 m@dL, the adjusted relative risks of Ml
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associated with these cutpoints were 0.9, 0.7, 1.2, 0.7, 1.4; (all p-values
nonsignificant, p-trend = 0.7). Analyaes limited to those with cholesterol > =
240 mg/dL or to individuals with elevated TcJHDLratios revealed similar null
findings.
Among those randomized to aspirin, the age-and smoking-adjusted rela-
tive risks (RRs) of first Ml associated with Lp(a) levels were 0.9,0.9, 1.5, 1.5,
1.0; (all p-valuee nonsignificant, p-trend = 0.9). Among those randomized to
placebo, the age-and amoking-adjustad RRs of first Ml aasooiated with Lp(a)
levels were 0.8,0.9, 1.4, 1,5, 1.3; (all p-values nonsignificant, p-trend =0.9).
No significant interaction was observed between Lp(a) and aspirin on risk of
firat Ml.
These data indicate that lipid parameters and aspirin use did not modify
the lack of overall effect of Lp(a) on the risk of first myocardiat infarction in
the Physicians’ Health Study.
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718-6 RedWine,WhiteWine,Liquor,Beer,andRiskof
CoronaryHospitalizations
A.L. Klatsky, fd.A. Armstrong, G.D, Friedman. Kaiser Pemranente Medical
Care Program, Oakland, CA, USA
International comparison data suggest that wine is more protective against
coronary heart disease (CHD) than beer or liquor, and there are potentially
protective antioxidants in wine, especially red wine. Yet prospective popu-
lation studies show no consensus about thia issue. We studied alcoholic
beverage choica in relation to later CHD hospitalizations among 128,934
pmons (n hospitalized = 3931). Cox propOrtional hazarda models with 9
covariates were used, plus a variable for drinka/day of each beverage type.
Categories of wine drinkers included red only, white only, both red and white
and “othet’. Total alcohol drinking was inversely related to CHD risk (p <
0.001) in each sex. In multivariate modela uncontrolled for total alcohol,
each beverage type ehowed apparent CHD protection; relative riaka (RR)
pardrinldday for all pemons follow: all wine = 0.8 (p < 0.01); liquor = 0.9 (p <
0.05); beer = 0.7 (p < 0.001). Controllad for total alcohol, theae relationships
lost significance (RR = 0.9 for wine or beec RR= 1.1 for liquor; p > 0.05).
Controlladfortotal alcohol, the RR’sforthewinesubsets follow: red only= 1.2
(p> 0.05); white only = 1.0 (p > 0.05); red and white = 0.8 (p < 0.05); other
wine = 0.08 (p > 0.05). Wald chi-square tests ahowed no significant CHD
risk differences between beverage typea and/or wine subsats. Theae data
aupporl the ooncluaion that alcohol drinking protects against CHD primarily
through effects of ethyl alcohol, because risk differences between beverage
types are minor.
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R. Mehran, G.S. Mintz, A.D. Pichard, K.M. Kent, L.F. Satler, J.J. Popma,
G. Bucher, M.B. Leon. Washington Hospital Center, Washington, DC, USA
To understand the proceas of diffuse in-stent restenosis, we analyzed the
clinical, procedural, quantitative angiographic {QCA, including lesion length
and reference and minimum lumen diameters (MLD), in mm}, and serial
(poet-intewention and follow-up) intravascular ultrasound (including refer-
ence, stent, lumen, and naointimal tissue (atent-lumen) areas, in mt172)in
201 stentad lesions. An injury score (IS) was constructed: O(PTCA preaaure
s16 atm & balloon:arlery ratio S1.1), 1 (PTCA pressure >16 atm or bal-
Ioon:artery ratio >1.1, and 2 (PTCA pressure =-16atm & balloon:arte~ ratio
>1 .1). Lesions were classified as no (neointimal tissue 575% stent area),
focal (neointimal tiasue >75% stent area, over s 10 mm stent length), and
diffuse restenosis (neointimal tissue >75% stent area, over >10 mm stent
length). Univariate predictors included:
Non(n= 56) Focal(n=63) Diffuse (n = 82) pANOVA
QCA
Lssionlength 6.20 + 5.65 7.69 + 5.13 10.67 & 700 0.0219
Refsrerrcalumen 3.31 & 0.77 2.67 & 0.52 2.71 + 0.55 <0.0001
FinalMLD 3.01 + 0.52 2.78 & 0,56 2.56 + 0.61 0.0002
Ultrasound
Reference lumen 12,75 & 6,90 8.44 +2.15 8.40 + 3.2 <0.0001
Stentares 9.61 & 3.9S 7.06 h 2.57 6.73 + 2.19 <0.0001
Is: 0/1/2 (%) 27i7310 15/66/19 20/51/29 0.0001
